StocksInsight

IMVT Stock vs the S&P 500: Returns, Risk and Crash History

Immunovant, Inc., healthcare (market value $6.0 billion): how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns and what analysts said. Returns to Oct 30, 2026; analyst data as of Nov 16, 2026.

Published Updated 4 min readHow we research

What changed since Nov 9

Exent re-checks this page every day. Ratings appear 30 days after they are published; the top‑ranked analysts’ calls are not counted here, they are in Gems.

76% Buy ratings (was 81%)

Key takeaways

  • IMVT returned +262.8% over the 5 years to Oct 30, 2026 versus +75.9% for the S&P 500: it beat the index.
  • Its 5-year Sharpe ratio was 0.58 against 0.58 for the S&P 500.
  • Its deepest crisis drawdown was −61.5% in the 2022 inflation bear market (S&P 500: −25.4%).
  • Five‑year volatility was 67.4% and beta 0.96.
  • 17 analysts rated it in the past year; 76% of their latest calls were Buy.
  • IMVT beat earnings estimates in 5 of its last 12 reports; the stock moved 6.7% on average, up or down, around each report.

What do the best‑ranked analysts on IMVT say now? See it in Exent Gems →

Did IMVT beat the S&P 500?

Over the 5 years to Oct 30, 2026, Immunovant, Inc. (IMVT) returned +262.8% including dividends, versus +75.9% for the S&P 500 (SPY). It beat the index by 186.9 percentage points, or +29.4% a year against +12.0%.

PeriodIMVTS&P 500IMVT per yearS&P 500 per yearResult
1 year+18.2%+12.0%+18.2%+12.0%Beat
3 years−11.7%+87.4%−4.1%+23.3%Lagged
5 years+262.8%+75.9%+29.4%+12.0%Beat
Period1 year3 years5 years
IMVT+18.2%−11.7%+262.8%
S&P 500+12.0%+87.4%+75.9%
IMVT per year+18.2%−4.1%+29.4%
S&P 500 per year+12.0%+23.3%+12.0%
ResultBeatLaggedBeat

Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also how to beat the S&P 500.

What Wall Street analysts say about IMVT

In the 12 months to 30 days ago, 17 analysts published 116 ratings on IMVT. Their latest calls were 76% Buy, 24% Hold and 0% Sell. 10 of them rank 4★ or higher in Exent’s analyst scoring, which is based on each analyst’s past price‑target hit rate and returns.

The consensus 12‑month price target was $40.00 (range $40.00–$40.00), +20.6% from the last price. Remember that the average analyst’s target is hit only about half the time: how accurate are price targets?

Top‑ranked analyst coveringFirmStarsPrice‑target hit rate
??????5.0★27.3%
Sam SlutskyLifeSci Capital5.0★30.1%
??????5.0★43.4%
??????4.9★36.9%
??????4.9★41.7%

Other analysts covering IMVT: Eddie Hickman · Danielle Brill

Ratings are shown with a 30‑day delay. Who the top‑ranked analysts on IMVT are, their live calls and the median target of only the top‑rated analysts are in Exent Gems.

The average analyst’s target is reached about 53.0% of the time; Exent Gems is built on the top 50 of Exent’s ranking,where some reached 90% or more over the last two years. Unlock the top 50 analysts.

IMVT returns by year vs the S&P 500

IMVT beat the S&P 500 in 3 of the 6 full calendar years shown.

YearIMVTS&P 500Difference
2026 (to Oct 30, 2026)+14.8%+11.7%+3.1%
2025+2.6%+17.7%−15.1%
2024−41.2%+24.9%−66.1%
2023+137.4%+26.2%+111.2%
2022+108.3%−18.2%+126.5%
2021−81.6%+28.7%−110.3%
2020+191.1%+18.3%+172.8%

IMVT risk-adjusted returns: Sharpe, Sortino and volatility

Over 5 years, IMVT had a Sharpe ratio of 0.58 against 0.58 for the S&P 500, so it earned less return per unit of risk than the index. Its annualized volatility was 72.5% and its beta 0.96: it tended to move about 1.0× as much as the market.

MetricIMVTS&P 500
Annual return+29.4%+12.0%
Volatility (annualized)72.5%15.5%
Sharpe ratio0.580.58
Sortino ratio1.550.91
Max drawdown (month-end)−65.1%−23.9%
Beta to the S&P 5000.961.00

Sharpe divides return above cash by total volatility; Sortino counts only downside volatility. Both use monthly returns and the 1–3 month T‑bill ETF (BIL) as the risk‑free rate.

How IMVT behaved in past crashes

IMVT’s deepest fall in the crises below was −61.5% in the 2022 inflation bear market, against −25.4% for the S&P 500. The last column turns that into money: what a $100,000 position would have lost from peak to trough.

CrisisIMVTS&P 500Loss on $100,000
COVID crash (Feb–Mar 2020)−50.9%−34.1%−$50,940
2022 inflation bear market−61.5%−25.4%−$61,460
2025 tariff selloff−37.4%−19.0%−$37,420
WindowIMVT max drawdown
Last 1 year−21.0%
Last 3 years−69.9%
Last 5 years−70.4%
Last 10 years−93.6%

Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the crash test.

What moves with IMVT, and what doesn’t

Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 60 months of monthly returns, IMVT’s correlation with the S&P 500 was 0.20, with the Nasdaq‑100 0.16, with long Treasuries (TLT) −0.06 and with gold (GLD) −0.10.

Adding a 5% IMVT position to an S&P 500 portfolio would have moved its 5‑year volatility from 15.5% to 15.8%.

Least correlated large capsCorrelationMost correlated large capsCorrelation
VZ−0.24CAT0.41
WM−0.20JPM0.34
CME−0.15ISRG0.34
META−0.15GILD0.34
SO−0.11VRT0.34

Holdings that are highly correlated behave like one position in a selloff. See how to find hidden overlap.

Latest IMVT upgrades, downgrades and price‑target changes

No named analyst changed a rating or price target on IMVT in the 5 weeks to Oct 20, 2026 (calls are shown 30 days after publication). The top‑ranked analysts’ calls are in Exent Gems. See all of the latest analyst upgrades and downgrades.

Do analysts get IMVT right?

Of the 276 analyst price targets on IMVT set from 2019 until a year ago, 36.2% were reached within 12 months (data to Oct 20, 2026), 32.4 points below the 68.6% hit rate of the median stock in Exent’s study of 794 stocks. Targets that were reached took a median of 81 days. The median target sat 61.0% above the share price on the day it was set.

Where analysts said IMVT would be by now: a year ago, 6 analysts had a price target on IMVT, and the median of their latest targets was $39.50. On Oct 20, 2026 IMVT closed at $28.61, 27.6% below it.

36.2%of targets reached within 12 monthsMedian stock: 68.6%
81 daysmedian time to reach a target
−27.6%price now vs the median target set a year ago
AfterCallsMove on the call3 months vs S&P 500
Upgrades of IMVT4+27.1%+21.9%
Upgrades, all stocks11,514+2.5%+3.4%
Downgrades of IMVT7−26.0%−39.5%
Downgrades, all stocks10,700−3.0%−1.6%

The move on the call runs from the close before the rating change to the close after it; the last column is the stock’s return minus the S&P 500’s over the next three months. Averages of rating changes on IMVT through Sep 15, 2026; analysts are not named here. Do analyst upgrades move stocks?

How IMVT moves after earnings

IMVT beat the consensus earnings‑per‑share estimate in 5 of its last 12 quarterly reports, through the one on Aug 6, 2026, and the revenue estimate in 0 of 1. From the close before each report to the close after it, the stock moved 6.7% on average, up or down, against 6.8% for the average report across the 1,002 US stocks Exent tracks. It rose after 6 of the 12 reports. In 2 of the 5 beats the stock still fell.

5/12earnings beats
±6.7%average move per report
6/12reports followed by a rise
ReportEPS vs estimateRevenue vs estimateStock move
Aug 6, 2026−$0.75 vs −$0.630.0%+1.7%
May 20, 2026−$0.73 vs −$0.59—+29.8%
Feb 6, 2026−$0.61 vs −$0.72—+14.3%
Nov 10, 2025−$0.73 vs −$0.72—−2.0%
Aug 11, 2025−$0.60 vs −$0.69—−1.6%
May 29, 2025−$0.64 vs −$0.71—+5.3%
Feb 6, 2025−$0.76 vs −$0.73—−9.3%
Nov 7, 2024−$0.74 vs −$0.61—−2.5%

Reported earnings per share against the consensus estimate, revenue surprise in percent, and the stock’s price change over the two sessions around the report. How stocks move after earnings

Are IMVT insiders buying or selling?

In the 12 months to Oct 20, 2026, IMVT insiders made no open‑market purchases and 52 sales worth $16.3 million, according to SEC Form 4 filings. The last open‑market purchase on record was on Dec 12, 2025.

After the 36 insider purchases of $10,000 or more since 2012, IMVT beat the S&P 500 by an average of 254.6 percentage points over the next 12 months; 74% of them were followed by a beat. Across all 17,865 insider purchases in Exent’s study, the average was +17.2% and the median +1.0% against the index.

Q1 ’25
Q2 ’25
Q3 ’25
Q4 ’25
Q1 ’26
Q2 ’26
Q3 ’26
Q4 ’26
DateInsiderRoleValue
Dec 12, 2025Roivant Sciences Ltd.Director, 10 percent owner$350.0 million
Jan 13, 2025Roivant Sciences Ltd.Director, 10 percent owner$336.9 million
Oct 2, 2023Roivant Sciences Ltd.Director, 10 percent owner$58.0 million
Oct 6, 2022Roivant Sciences Ltd.Director$2.5 million
Sep 30, 2022Pande AtulDirector$84,000

The table lists the latest open‑market purchases on record, leaving out the last 30 days. The chart counts Form 4 purchases and sales by calendar quarter. Purchases are open‑market buys; sales include planned sales under 10b5‑1 trading plans. Do insider buys beat the market?

How much of IMVT is sold short?

As of the Sep 30, 2026 settlement date, 20.53% of IMVT’s float was sold short: 17.4 million shares, or 9.6 days of average trading volume to cover. A year earlier (Oct 15, 2025) it was 20.05%. The median across the 997 US stocks Exent tracks was 4.77%, so IMVT is more heavily shorted than most.

  • Apr 30, 202621.91%
  • May 29, 202622.64%
  • Jun 30, 202621.21%
  • Jul 31, 202619.30%
  • Aug 31, 202618.61%
  • Sep 30, 202620.53%

From FINRA short‑interest reports, filed twice a month; the bars show the short share of the float at each month‑end. Days to cover divides the shares short by the average daily volume. The most shorted stocks

How many institutions own IMVT?

At the end of Q2 2026 (Jun 30, 2026), 240 institutions reported holding IMVT in 13F filings, up 13 from the quarter before and up from 181 a year earlier. Their reported holdings add up to 54.0% of IMVT’s shares. In the quarter 113 institutions added to their positions and 82 cut them.

24013F holders
41new positions
27positions closed
54.0%of shares held by 13F filers

Investment managers with over $100 million in US equities file 13F reports within 45 days of each quarter end, so this is the latest complete quarter. Holdings can add up to more than 100% when shares are lent and counted twice. Which stocks institutions are buying and selling

Is IMVT diluting shareholders?

IMVT’s diluted share count rose 107.9% over the five fiscal years to fiscal 2026 and rose 20.4% in fiscal 2026 alone. Each share now owns a smaller slice of the company. The median change across the 1,005 US stocks Exent tracks was −0.1%.

Stock‑based compensation was $55.7 million in fiscal 2026. IMVT did not buy back shares in fiscal 2026.

+20.4%share count, 1 year
+107.9%share count, 5 years
0.00%buyback yield

Weighted‑average diluted shares from IMVT’s annual income statements; stock‑based compensation and buybacks from its cash‑flow statement. Stock dilution and stock‑based compensation, explained

IMVT financial health scores

In Exent’s Oct 20, 2026 snapshot, IMVT’s Altman Z‑score was 25.07, in the safe zone (where 465 of the 794 non‑financial US stocks Exent tracks sit). Its Piotroski F‑score was 3 out of 9; 94% of scored stocks reach 3 or more.

25.07Altman Z‑score: safe zone
3/9Piotroski F‑score

The Altman Z‑score combines five balance‑sheet and earnings ratios into one bankruptcy‑risk score: below 1.81 is the distress zone, 1.81–2.99 grey, above 2.99 safe. It is not meaningful for banks, insurers and REITs. The Piotroski F‑score counts nine yes/no tests of profitability, leverage and efficiency; 8–9 is strong, 0–2 weak. Both come from the latest annual statements. Which stocks have the highest bankruptcy risk?

Which ETFs hold IMVT?

As of Oct 20, 2026, 17 of the 304 ETFs Exent tracks held IMVT. Its largest weight is in XBI (State Street SPDR S&P Biotech ETF), at 0.60% of the fund.

ETFFundWeight of IMVT
XBIState Street SPDR S&P Biotech ETF0.60%
IWOiShares Russell 2000 Growth ETF0.17%
VTWOVanguard Russell 2000 Index Fund0.10%
VBKVanguard Small-Cap Growth Index Fund ETF Shares0.09%
IWMiShares Russell 2000 ETF0.08%
SCHASchwab U.S. Small-Cap ETF0.06%
SCHMSchwab U.S. Mid-Cap ETF0.05%
GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETF0.05%

Owning several of these funds stacks the same position. How much do VOO, QQQ and VTI overlap?

The right benchmark for IMVT

Exent matches every holding to the index with the most similar risk. For IMVT that is MDY. Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read why the S&P 500 is the wrong benchmark for most portfolios.

Other healthcare stocks

TickerName5‑year returnVolatility (5y)
LLYEli Lilly and Company+482.3%32.6%
JNJJohnson & Johnson+92.9%16.8%
ABBVAbbVie Inc.+207.1%23.5%
RYTMRhythm Pharmaceuticals, Inc.+704.3%74.0%
KODKodiak Sciences Inc.+323.5%99.3%
TFXTeleflex Incorporated−59.3%35.1%
LGNDLigand Pharmaceuticals Incorporated+254.5%44.4%
DOCSDoximity, Inc.−52.8%63.3%

Data and methodology

Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: Exent methodology.

Company data as of Oct 20, 2026. The move around an earnings report runs from the close before it to the close after it; a price target counts as hit when the stock closed at or beyond it within 12 months (Exent analyst data). Revenue by region and segment, share counts and executive pay come from company filings; insider trades from SEC Form 4, short interest from FINRA, institutional ownership from 13F filings, Congress trades from STOCK Act disclosures filed with the House and Senate, federal contracts from USAspending.gov. Filings from the last 30 days are shown as counts only.

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Check IMVT with Exent Gems

Wall Street’s average IMVT price target is 20.6% above the latest share price. See what the best‑ranked analysts on IMVT say now in Exent Gems.

  1. Exent ranks Wall Street analysts by their past price‑target hit rate and returns, and keeps the best‑ranked few.
  2. Gems shows who the top‑ranked analysts covering IMVT are, their live calls and the median target of only the top‑rated analysts.
  3. Gems flags the stocks where several top‑ranked analysts agree: a starting point for your own research, not a promise.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

Yes. IMVT returned +262.8% (+29.4% a year) over the 5 years to Oct 30, 2026, versus +75.9% (+12.0% a year) for the S&P 500, including dividends.

No. As of Oct 20, 2026, IMVT (Immunovant, Inc.) is not one of the 503 stocks in the S&P 500.

No. As of Oct 20, 2026, IMVT (Immunovant, Inc.) is not one of the 101 stocks in the Nasdaq-100.

IMVT fell −50.9% from peak to trough during the covid crash (feb–mar 2020), versus −34.1% for the S&P 500.

IMVT fell −61.5% from peak to trough during the 2022 inflation bear market, versus −25.4% for the S&P 500.

Over the 5 years to Oct 30, 2026, IMVT’s Sharpe ratio was 0.58 and its Sortino ratio 1.55, versus 0.58 and 0.91 for the S&P 500.

IMVT’s 5‑year annualized volatility was 67.4%, higher than the S&P 500’s 17.0%, with a beta of 0.96.

Among large US stocks, the lowest correlations with IMVT over the last 60 months were VZ (−0.24), WM (−0.20), CME (−0.15). Its correlation with long Treasuries (TLT) was −0.06 and with gold (GLD) −0.10.

IMVT beat the consensus earnings-per-share estimate in 5 of its last 12 quarterly reports through Aug 6, 2026, and the revenue estimate in 0 of 1. The stock moved 6.7% on average, up or down, from the close before each report to the close after it.

As of the Sep 30, 2026 settlement date, 20.53% of IMVT’s float was sold short (17.4 million shares, 9.6 days to cover), according to FINRA short-interest reports. A year earlier it was 20.05%.

Yes. IMVT’s diluted share count rose 107.9% over the five fiscal years to fiscal 2026 and rose 20.4% in the latest year.

What do the best‑ranked analysts say on IMVT now?

Exent ranks Wall Street analysts by their track record. Gems shows who the top‑ranked analysts on IMVT are, their latest calls and the stocks where several of them agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.